Sugi Predict

Sugi Predict / Compounds / SCHEMBL6526529

SCHEMBL6526529

SCHEMBL6526529

O=C1c2ccccc2C(=O)N1OCC(O)CO

nearest known ligand 0.61

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.61
▸ SMN1; SMN2 Q16637 1/20 0.61
▸ GAA P10253 1/20 0.51
▸ ALDH1A1 P00352 5/20 0.49
▸ CYP1A2 P05177 2/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ KMT2A Q03164 4/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ MAPT P10636 1/20 0.45
▸ HPGD P15428 1/20 0.43
▸ ATM Q13315 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.41
▸ RECQL P46063 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26249820 1.00 POLB (0.61) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL529416 0.91 POLB (0.70) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL28334287 0.82 POLB (0.48) POLBSMN1; SMN2CYP1A2KMT2AMEN1
SCHEMBL2296725 0.81 POLB (0.58) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL31208299 0.81 POLB (0.58) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL2296722 0.81 POLB (0.58) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL28675859 0.79 POLB (0.54) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL527771 0.78 GAA (0.58) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL8752996 0.78 POLB (0.56) POLBSMN1; SMN2GAAALDH1A1CYP1A2
SCHEMBL3978571 0.77 POLB (0.55) POLBSMN1; SMN2GAAALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107586291-B A kind of synthetic method of razaxaban metabolin 5 梯尔希（南京）药物研发有限公司 2019-08-20 — — CN claimed
CN-110054623-A A kind of preparation method of Rivaroxaban intermediate 浙江燎原药业股份有限公司 2019-07-26 — — CN claimed
CN-107586291-A A kind of synthetic method of razaxaban metabolin 5 梯尔希（南京）药物研发有限公司 2018-01-16 — — CN claimed
US-20220168433-A1 PROGRAMMABLE POLYMERIC DRUGS Sony Group Corporation (JP) 2022-06-02 — — US disclosed
US-20220168435-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2022-06-02 — — US disclosed
US-20220160887-A1 PROGRAMMABLE POLYMERIC DRUGS Sony Group Corporation (JP) 2022-05-26 — — US disclosed
US-10844076-B2 Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine NEKTAR THERAPEUTICS (US) 2020-11-24 — — US disclosed
US-10844076-B2 Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine NEKTAR THERAPEUTICS (US) 2020-11-24 — — US disclosed
WO-2020210689-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210694-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
WO-2020210692-A1 PROGRAMMABLE POLYMERIC DRUGS SONY CORPORATION (JP) 2020-10-15 — — WO disclosed
US-20120302570-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2012-11-29 — — US disclosed
US-20120302570-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2012-11-29 — — US disclosed
EP-2467383-A1 HETEROCYCLIC OXIME COMPOUNDS Novartis AG (CH) 2012-06-27 — — EP disclosed
US-20110065708-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-03-17 — — US disclosed
US-20110065708-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-03-17 — — US disclosed
US-20110065708-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-03-17 — — US disclosed
WO-2011020861-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-02-24 — — WO disclosed
WO-2011020861-A1 HETEROCYCLIC OXIME COMPOUNDS NOVARTIS AG (CH) 2011-02-24 — — WO disclosed
EP-0094586-A2 Glycerol derivatives, process for preparing same and pharmaceutical composition containing same ONO PHARMACEUTICAL CO., LTD. (JP) 1983-11-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844076-B2 Derivatives of 6-(2,3-dichlorophenyl)-1,2,4-triazin-5-amine KCNJ2, TRPC5, RYR2 POLB 4480/4885SMN1; SMN2 3458/4885GAA 2406/4885
US-20220160887-A1 PROGRAMMABLE POLYMERIC DRUGS CHRM1, NCL, PBRM1 POLB 887/4885SMN1; SMN2 849/4885GAA 793/4885
US-20220168433-A1 PROGRAMMABLE POLYMERIC DRUGS CHRM1, PBRM1, CHRM2 POLB 1035/4885SMN1; SMN2 864/4885GAA 613/4885
US-20110065708-A1 HETEROCYCLIC OXIME COMPOUNDS MET, ERBB2, TIE1 POLB 3903/4885SMN1; SMN2 599/4885GAA 2312/4885
US-20220168435-A1 PROGRAMMABLE POLYMERIC DRUGS CHRM1, PBRM1, CHRM2 POLB 1019/4885SMN1; SMN2 845/4885GAA 600/4885
US-20120302570-A1 HETEROCYCLIC OXIME COMPOUNDS MET, ERBB2, TIE1 POLB 3903/4885SMN1; SMN2 599/4885GAA 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.